Sp1 is involved in H2O2-induced PUMA gene expression and apoptosis in colorectal cancer cells
© Wang et al; licensee BioMed Central Ltd. 2008
Received: 15 July 2008
Accepted: 24 September 2008
Published: 24 September 2008
Reactive oxygen species (ROS) are intricately involved in tumor progression through effects on proliferation, apoptosis and metastasis. But how ROS works is not well understood. In previous study, we found PUMA (p53-upregulated modulator of apoptosis) played an important role in oxaliplatin-induced apoptosis. In the present study, we detect the role of PUMA in H2O2-induced apoptosis in colorectal cancer cells and investigate the potential mechanism.
Methods and results
We showed that H2O2 stimulated the activity of a 493 PUMA promoter reporter gene construct. Suppressing the expression of PUMA abrogated H2O2-induced apoptosis. Deletion of the Sp1-binding sites also decreased the transactivation of PUMA promoter by H2O2. Furthermore, induction of PUMA promoter activity by H2O2 was abrogated by PFT-α (a p53 inhibitor) and Mithramycin A (a Sp1 inhibitor), as compared with PFT-α alone. To determine the effects of Sp1 on PUMA in H2O2-induced apoptosis, procaspase 3, procaspase 9 and procaspase 8 expression was assessed. Mithramycin A and PFT-α also reduced H2O2-induced apoptosis synergistically and abrogated the expression of procaspase 3 and procaspase 9.
Our findings suggest that PUMA plays a role in H2O2-induced apoptosis, and that Sp1 works together with p53 in the regulation of H2O2-induced PUMA expression and apoptosis in colorectal cancer cells. This study provides important regulatory insights in the mechanisms of ROS in colorectal cancer.
Recently, a large body of evidence indicates that ROS plays a central role in intracellular and intercellular signal transduction pathway in a variety of cellular process. Reactive oxygen species (ROS) increased in colorectal cancer due to increased aerobic metabolism and exposure to various anti-cancer modalities such as ionizing radiation and chemotherapeutic drugs . Many factors are involved in this process. ROS are capable of activating certain transcription factors directly and thereby modulating the regulation of gene transcription. Several transcriptional factors such as AP1, Sp1 [2, 3], Smad  and snail are potentially associated with ROS-triggered cellular process. Apoptosis and cancer are opposed phenomena but ROS have been widely reported to play a key role in both[5, 6], suggesting that the regulation of gene expression by oxidants, antioxidants and the redox state remains as a promising therapeutic approach. Hyperphysiological levels of ROS cause DNA damage, mutation and activation of several proto-oncogenes in normal cells [7, 8]. On the other hand, the DNA damage and initiation of signal transduction pathways caused by ROS contribute to the cytotoxicity to cancer cells . The mechanism involved is still controversial and its ability to induce apoptosis in colorectal cancer is not yet fully understood.
It is generally recognized that oxidative stress is associated with p53-dependent cell cycle arrest, DNA repair and apoptosis [10, 11], but a clear understanding of the downstream regulation mechanisms is still elusive. It has been proposed that Bcl-2 regulates antioxidant pathways at sites of free radical generation . Another gene, called p53 upregulated modulator of apoptosis (PUMA), was identified through global profiling as a p53-inducible gene. Yeast two-hybrid screening identified PUMA as a Bcl-2 interacting protein . PUMA is a proapoptotic member of the Bcl-2 family and plays an important role in stress-induced apoptosis. Yu et al  suggested that PUMA could be directly activated by p53 through p53-responsive elements in its promoter region. The protein encoded by PUMA was exclusively localized to mitochondria where it interacted with Bcl-2 and Bcl-xl through its BH3 domain . We have previously shown that oxaliplatin-induced ERK inactivation was involved in the regulation of oxaliplatin-induced PUMA expression and apoptosis . We hypothesized that ROS had a direct effect on PUMA.
In the present study, we found that PUMA plays a role in H2O2-induced apoptosis in colorectal cancer cells. The effects of H2O2 on the expression of PUMA and the mechanism by which this is regulated were examined. Our results suggest that Sp1 plays a role in H2O2-induced PUMA expression and apoptosis in colorectal cancer cells. Comprehensive understanding of the ROS-triggered signal transduction, transcriptional activation and regulation of gene expression will help to identify the critical role of ROS in tumor progression and in defining a strategy for chemo-therapeutic intervention.
Materials and methods
All reagents for cell culture were purchased from Invitrogen/Life Technologies (Carlsbad, CA, USA). Mithramycin A (Mithr.A), pifithrin-alpha (PFT-α), Hoechest dye 33258, H2O2 and anti-PUMA antibody were purchased from Sigma-Aldrich (St-Louis, MI, USA). Anti-procaspase 3, 9, 8 antibodies were purchased from Cell Signaling (Beverly, MA). Anti-P53 (DO-1) antibody, anti-Sp1 (polyclonal antibody PEP2) antibody, anti-actin antibody and secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Sp1 siRNA, control siRNA, siRNA Transfection reagent and siRNA Transfection Medium were purchased from Santa Cruz Biotechnology. All other chemicals were of analytical grade.
The -336/+157 and -36/+157 PUMA-Luc reporter plasmids were a kind gift from Dr. Bert Vogelstein (Johns Hopkins University, Baltimore, MD, U.S.A.). The (-336/+157 -126/-25) PUMA-Luc plasmid was constructed by digesting the -336/+157 PUMA-Luc plasmid with Sac II and SmalI, and re-ligation according to reference 16. pSVβ-Galactosidase plasmid was purchased from promega.
Cell culture, transient transfections and luciferase assays
The human colorectal cancer cell lines LoVo and HCT116 were obtained from American Type Culture Collection (Manassaas, VA), LoVo PUMA_AS cells was established as described in a previous study. The LoVo cells and LoVo PUMA_AS cells were cultured in 25 cm2 flasks in 1640 medium contained 10% (v/v) FBS with or without G418 (600 μg/ml). Cells were maintained at 37°C in a humidified 5% CO2 atmosphere until confluency and subcultured (1:10 split ratio) using trypsin (0.05% w/v)/EDTA (0.02% w/v). Cells for examination were grown in six-well cluster dishes. All treatments were carried out on cells at 70–80% confluence, PFT-α (20 μM) and Mithr.A (200 ng/ml) were added an hour before addition of H2O2.
Transient transfection was performed in 6-well plates using Lipofectamin 2000(Invitrogen) according to the manufacture's instructions. Cells were transfected with 0.5 μg luciferase reporter plasmid and 0.1 μg pSVβ, transfections were allowed to proceed for 3 hours in the absence of serum and the cells recovered in medium supplemented with reduced serum level(2.5%) for 21 hours. Luciferase assays were performed 48 hours later using the luciferase assay kit from Promega, according to the manufacture's instructions (Promega, Madison, WI). The β-galactosidase reporter pSVβ (Promega) was included to control for transfection efficiency.
Reverse transcriptase-polymerase chain reaction
0.5 μg total RNA was isolated from the cells using TRIZOL (Gibco). PUMA mRNA expression was determined by RT-PCR analysis using a RevertAid First Strand cDNA Synthesis Kit (MBI) and PCR kit (SBS Genetech Co. Ltd., Beijing, China). The two gene-specific primers used for amplification were as follows: (upper) gacgacctcaacgcacagta and (lower) ccagggtgtcaggaggtg. PCR products were electrophoresed in 1.5% agarose gel. Beta-actin mRNA was also amplified as an internal control. The experiment was performed twice.
Western blotting analysis of PUMA, p53, Sp1, procaspase 3,9 and procaspase 8 expression
Western blotting analysis was assessed according to the protocol described before. In brief, cells were washed with ice-cold PBS twice and lysed with ice-cold lysis buffer. Protein samples (15 μg) were separated by SDS/PAGE (12% acrylamide gel) using a Bio-Rad Mini-Protean III system. Proteins were transferred to PVDF membranes and the membranes were blocked for 1 hour at room temperature with TBST. Blots were then incubated at room temperature with primary antibodies (1:500 dilution) and then primary antibodies were removed and the blots were extensively washed with TBS/Tween 20 for three times. Blots were then incubated for 1 hour at room temperature with the secondary antibodies (1: 2000 dilution). Then blots were extensively washed as above for 1 hour and developed using the Enhanced Chemiluminescence detection system and quantified using the GeneTools systems.
siRNA transfection was performed according to the manufacture's instructions. In brief, LoVo cells were seeded at a density of 2 × 105 per well in 2 ml antibiotic-free 1640 medium supplemented with 10% FBS in a six well tissue plate. The cells were incubated at 37°C in a CO2 incubator until the cells were 70% confluent. siRNA duplex solution (6 μl of siRNA duplex in 100 μl siRNA Transfection Medium) was added directly to the dilute Transfection Reagent (6 μl of siRNA Transfection Reagent in 100 μl siRNA Transfection Medium). The mixture was mixed and incubated at room temperature for 30 minutes. Then the mixture and 0.8 ml siRNA Transfection Medium were mixed and added to the cells. The cells were incubated 6 hours and the mixture was removed. H2O2 (0.64 mM) was added 24 hours later and remained for 15 minutes. Western blotting analysis was performed 48 hours post-transfection.
Hoechst 33258 staining for apoptosis
For analysis of apoptosis by nuclear staining with Hoechst dye 33258 (Sigma Chemical Co.), cells were stimulated according to experimental protocols, washed once with PBS, and then fixed with pre-cooled methanol 500 μl/well for 10 minutes. After fixation, cells were washed once with PBS, stained with 1 μM Hoechst dye 33258 for 10 minutes, and then washed once with PBS and distilled water. Apoptosis was indicated by the presence of condensed or fragmented nuclei which bind the Hoechst dye 33258 with high affinity. For analysis of cell structure by photomicroscopy, coverslips were washed once with PBS and then inverted and mounted on to glass slides. Cells were visualized using an Olympus microscope. Two hundred cells in three randomly chosen fields were counted and scored for the incidence of apoptotic chromatin changes under fluorescence microscopy.
All data are presented as mean values ± standard deviation (SD) of three independent experiments. Comparison of the effects of various treatments was performed using factor analysis, one-way ANOVA analysis of variance and a two-tailed t-test. Difference with a p value of < 0.05 were considered statistically significant.
H2O2induces time- and dose-dependent PUMA expression and apoptosis in colorectal cancer cells
To assess the effects of H2O2 on apoptosis in colorectal cancer, we exposed LoVo cells to a dose range of H2O2 at different time points, and we measured apoptosis by Hoechst 33258 dye 24 hours later. As shown in Figure 1C, H2O2-induced apoptosis increased significantly at 15 minutes and decreased after 30 minutes. And apoptosis increased significantly when LoVo cells were treated for 15 minutes with 0.64 mM and 0.80 mM of H2O2. (Figure 1D).
H2O2up-regulates PUMA expression at the transcriptional level in colorectal cancer cells
Activation of p53 by e.g. DNA-damaging agents is followed by an induction of PUMA expression, leading to enhanced recruitment of endogenous p53 protein to the PUMA gene promoter. To test this, we used a -336/+157 PUMA-Luc reporter plasmid, which contains a set of 10 potential binding sites for Sp family proteins in the proximal region between nucleotides-120 and 18, flanked by two p53-recognition sequences at the 5' end between nucleotides -229/-209 and -145/-126. LoVo cells were transfected with this vector, 24 hours before H2O2 (0.64 mM) was added. As shown in Figure 2C, a significant transactivation of this promoter was observed after exposure to H2O2 for 15 minutes. These results suggest that H2O2 can influence endogenous PUMA levels by regulating PUMA promoter activity.
H2O2-induced apoptosis is abrogated by suppression of PUMA expression
Sp1 is required for the transactivation of the human PUMA promoter by p53
PFT-α is a stable, water soluble inhibitor of p53-dependent apoptosis and was also shown to reduce the activation of p53-regulated genes . Mithramycin A (Mithr.A) is a drug which has been clinically used in the therapies of several type of cancer and Paget's disease. It binds to GC-rich regions in chromatin and interferes with the transcription of genes that bear GC-rich motifs in their promoters including Sp1. Previous study suggested that Mithr.A also activates endogenous p53 protein and has no effect on the expression of endogenous Sp1 genes. To identify the effects of Mithr.A on p53 and Sp1 expression, Mithr.A (200 ng/ml) was added to LoVo cells 24 hours before p53 and Sp1 expression was assessed by Western blotting analysis. As shown in Figure 4B, Mithr.A had no effects on p53 expression, but suppressed the expression of Sp1. Mithr.A also abrogated the Sp1 expression induced by H2O2 (Figure 4C). Similarly, PFT-α (20 μM) abrogated p53 expression induced by H2O2.
To determine the effects of Mithr.A and PFT-α on PUMA expression, Mithr.A and PFT-α were added an hour before H2O2 treatment. As shown in Figure 4D, PUMA expression was found to be suppressed by exposure to Mithr.A as well as to PFT-α, and more markedly when both compounds were combined. To determine whether these effects were cell-specific, we also assessed PUMA expression in HCT116 cells and gained the same results (Figure 4E). To confirm the role of Sp1 in H2O2-induced PUMA expression furthermore, we suppressed Sp1 expression by transfecting Sp1 siRNA and our data suggested that Sp1 siRNA abrogated H2O2-induced PUMA expression (Figure 4F).
To understand the mechanism of Mithr.A and PFT-α action, we tested the ability of Mithr.A and PFT-α to inhibit PUMA promoter activation induced by H2O2. As shown in Figure 4G, Mithr.A caused a decrease in PUMA promoter activity induced by H2O2 but the difference was not significant (p < 0.05). PFT-α, in contrast, caused a significant decrease in PUMA expression (p < 140.05). Combination of PFT-α and Mithr.A caused a significant enhancement of decrease in PUMA promoter activity (p < 0.05). Factor analysis (n = 6) indicated that Mithr.A and PFT-α have synergistic effects on H2O2-induced PUMA promoter activation (F = 5.480, p = 0.030).
H2O2-induced apoptosis is abrogated by Mithr.A and PFT-α through a mitochondrial pathway
PUMA is a mitochondrial protein involved in apoptosis in a mitochondrial pathway, leading to activation of caspase 9 and caspase 3 but not caspase 8. To assess the impact of Mithr.A and PFT-α treatment on these events, total cell extracts were prepared from H2O2, Mithr.A and PFT-α treated cells, and procaspase 3, procaspase 9 and procaspase 8 levels were monitored by Western blotting analysis. As shown in Figure 5B, increased levels of procaspase 3 and 9 were observed in Mithr.A and PFT-α treated cells, while effects on procaspase 8 were absent.
The generation of large amounts of reactive oxygen intermediates may contribute to the ability of some tumors to mutate, inhibit antiproteases and injure local tissues . On the other hand, the production of ROS during the catabolism of tumor and chemotherapy leads to apoptosis and benefits in the process of the clearance of tumor cells. In the present study, we found that H2O2 up-regulated PUMA expression and induced apoptosis in colorectal cancer LoVo cells. Suppression of PUMA expression abrogated H2O2-induced apoptosis. To further elucidate the mechanism responsible for the changes in amounts of PUMA, we determined levels of PUMA mRNA by RT-PCR. Our data suggested that PUMA expression at the mRNA level increased and transcription activity of PUMA was upregulated by administration of H2O2 especially at doses between 0.04 and 0.64 mM in colorectal cancer LoVo cells.
PUMA is essential in the process of apoptosis induction by exogenous or endogenous p53 [20–22]. However, many studies described that there were other factors involved in the regulation of PUMA expression, either in a p53-dependent or independent manner including our previous report. For example, Tzippi et al  reported E2F1 upregulated the expression of PUMA through a direct transcriptional mechanism and increased PUMA levels mediated E2F1-induced apoptosis. Furthermore, Koutsodontis et al  found that the PUMA promoter contains a cluster of GC-rich motifs flanked by two p53-recognition motifs and a series of Sp1 recognition sites at the 5'-end. This was identified by searching the 5'-flanking sequence of PUMA with Tfsearch software http://molsun1.cbrc.aist.go.jp/research/db/TFSEARCH.html. The same report also suggests that the Sp family was essential for the cellular response to p53 activation by genotoxic stress such as ROS [24, 25]. This urged us to hypothesize that Sp1 plays a role in H2O2-induced PUMA expression and apoptosis.
To investigate the role of Sp1 on H2O2-induced PUMA expression, Mithr.A (a DNA-binding antitumor agent)  and PFT-α (a selective p53 inhibitor), were used for pharmacological intervention both in LoVo cells (p53 mutation) and HCT116 cells (p53 wide type). Sp1 siRNA was also used to confirm the result. Our data suggest that Sp1 plays a role in H2O2-induced PUMA expression and regulated it at the transcriptional level. This regulation is not cell specific in LoVo cells and HCT116 cells. To determine whether H2O2 could induce PUMA expression in p53 mutant cell lines, we detect the expression of PUMA in H2O2-treated SW480 cells(p53 mutated colorectal cancer cells) and LoVo p53- cells (established in our previous study). Our data showed that no much difference was found in H2O2 -treated cells and untreated cells (data not show) and this induction was p53-dependent.
Sp1 and p53 could regulate PUMA expression synergistically in H2O2-treated LoVo colorectal cancer cells. More interesting, Mithr.A was used as an antitumor agent and has been used in the clinic for several types of cancer. Lee et al  reported that it sensitized cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Our data suggest that Mithr.A decreases apoptosis in colorectal cancer cells through inhibiting PUMA promoter activity, which may limit the application of Mithr.A in colorectal cancer therapy.
To assess whether inhibiting Sp1 binding to the PUMA promoter by Mithr.A contributed to a decrease of apoptosis induced by H2O2, Hoechst dye 33258 staining was carried out. Our data showed that combination of Mithr.A and PFT-α abrogated H2O2-induced apoptosis significantly better, as compared with PFT-α alone. PUMA induction results in Bax multimerizaion, mitochondia-dependent death, the release of cytochrome C and caspase 9 induction leading to apoptosis . Our data showed an increase in expression of procaspase 3, procaspase 9 and suggested an decrease of caspase 3 and 9. Therefore, Sp1 activity may be functionally linked to the effects of H2O2 on PUMA.
In summary, a novel mechanism of PUMA stimulation by H2O2 in colorectal cancer LoVo cells has been demonstrated. The results suggest that H2O2-induced up-regulation of PUMA is partly due to Sp1 transcription factor except for p53. These results may provide an insight into the molecular control of H2O2-induced PUMA expression in colorectal cancer cells through Sp1 binding sites.
The authors thank Dr. Bert Vogelstein for providing the -336/+157 and -36/+157 PUMA-Luc reporter plasmids.
- Allen RG, Tresini M: Oxidative stress and gene regulation. Free Radic Biol Med. 2000, 28: 463-499. 10.1016/S0891-5849(99)00242-7.View ArticleGoogle Scholar
- Dasari A, Bartholomew JN, Volonte D, Galbiati F: Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/sp1-mediated activation of two GC-Rich promoter elements. Cancer Res. 2006, 66: 10805-10814. 10.1158/0008-5472.CAN-06-1236.View ArticleGoogle Scholar
- Carnesecchi S, Carpentier JL, Foti M, Szanto : Insulin-induced vascular endothelial growth factor expression is mediated by the NADPH oxidase NOX3. Exp Cell Res. 2006, 312: 3413-3424. 10.1016/j.yexcr.2006.07.003.View ArticleGoogle Scholar
- Lai CF, Feng X, Nishimura R, Teitelbaum SL, Avioli LV, Patrick Ross F, Cheng SL: Transforming growth factor-beta upregulates the beta 5 integrin subunit expression via Sp1 and Smad signaling. Journal of Biological Chemistry. 2000, 275: 36400-36406. 10.1074/jbc.M002131200.View ArticleGoogle Scholar
- Liu G, Chen X: The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene. 2002, 21: 7195-7204. 10.1038/sj.onc.1205862.View ArticleGoogle Scholar
- Izeradjene K, Douglas L, Tillman DM, Delaney AB, Houghton JA: Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Cancer Res. 2005, 65: 7436-7445. 10.1158/0008-5472.CAN-04-2628.View ArticleGoogle Scholar
- Milano A, Montesano Gesualdi N, Teperino R, Esposito F, Cocozza S, Ungaro P: Oxidative DNA damage and activation of c-Jun N-terminal kinase pathway in fibroblasts from patients with hereditary spastic paraplegia. Cell Mol Neurobiol. 2005, 25: 1245-1254. 10.1007/s10571-005-8501-2.View ArticleGoogle Scholar
- Felty Q, Xiong WC, Sun D, Sarkar S, Singh KP, Parkash J, Roy D: Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. Biochemistry. 2005, 44: 6900-6909. 10.1021/bi047629p.View ArticleGoogle Scholar
- Karihtala P, Soini Y: Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS. 2007, 115: 81-103. 10.1111/j.1600-0463.2007.apm_514.x.View ArticleGoogle Scholar
- Bragado P, Armesilla A, Silva A, Porras A: Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis. 2007, 12: 1733-1742. 10.1007/s10495-007-0082-8.View ArticleGoogle Scholar
- Macip S, Kosoy A, Lee SW, O'Connell MJ, Aaronson SA: Oxidative stress induces a prolonged but reversible arrest in p53-null cancer cells, involving a Chk1-dependent G2 checkpoint. Oncogene. 2006, 25: 6037-6047. 10.1038/sj.onc.1209629.View ArticleGoogle Scholar
- Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993, 75: 241-251. 10.1016/0092-8674(93)80066-N.View ArticleGoogle Scholar
- Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B: PUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells. Molecular Cell. 2001, 7: 673-682. 10.1016/S1097-2765(01)00213-1.View ArticleGoogle Scholar
- Shaltouki A, Freer M, Mei Y, Weymanc M: Increased expression of the pro-apoptotic Bcl-2 family member PUMA is required for mitochondrial release of cytochrome C and the apoptosis associated with skeletal myoblast differentiation. Apoptosis. 2007, 12: 2134-2154. 10.1007/s10495-007-0135-z.View ArticleGoogle Scholar
- Wang XY, Li M, Wang JD, Yeung CM, Zhang HQ, Kung HF, Jiang B, Lin MC: The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. Biochem Pharm. 2006, 71: 1540-1550. 10.1016/j.bcp.2006.02.011.View ArticleGoogle Scholar
- Koutsodontis G, Vasilaki E, Chou WC, Papakosta P, Kardassis D: Physical and functional interactions between members of the tumor suppressor p53 and the Sp1 families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem J. 2005, 389: 443-445. 10.1042/BJ20041980.View ArticleGoogle Scholar
- Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov : AVA chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999, 285: 1733-1737. 10.1126/science.285.5434.1733.View ArticleGoogle Scholar
- Synder RC, Ray R, Blume S, Miller DM: Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters. Biochemistry. 1991, 30: 4290-4297. 10.1021/bi00231a027.View ArticleGoogle Scholar
- Szatrowski PC, Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991, 51: 794-798.Google Scholar
- El-Deiry WS: Regulation of p53 downstream genes. Semin cancer biol. 1998, 8: 345-357. 10.1006/scbi.1998.0097.View ArticleGoogle Scholar
- Yu J, Wang ZG, Kinzler KW, Vogelstein B, Zhang L: PUMA mediates the apoptosis response to p53 in colorectal cancer. Proc Natl Acad Sci. 2002, 100: 1931-1936. 10.1073/pnas.2627984100.View ArticleGoogle Scholar
- Han J, Flemington C, Houghton AB, Gu Z, Zambetti GP, Lutz RJ, Zhu L, Chitteden T: Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci. 2001, 98: 11318-11323. 10.1073/pnas.201208798.View ArticleGoogle Scholar
- Hershko T, Ginsberg D: Up-regulation of Bcl-2 Homology 3 (BH3)-only Proteins by E2F1Mediates Apoptosis. J Biol Chem. 2004, 279: 8627-8634. 10.1074/jbc.M312866200.View ArticleGoogle Scholar
- Liu JW, Chandra D, Rudd MD, Butler AP, Pallotta V, Brown D, Coffer PJ, Tang DG: Induction of prosurvival molecules by apoptotic stimuli: Involvement of FOXO3a and ROS. Oncogene. 2005, 24: 2020-2031. 10.1038/sj.onc.1208385.View ArticleGoogle Scholar
- Wu WS: The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 2006, 25: 695-705. 10.1007/s10555-006-9037-8.View ArticleGoogle Scholar
- Synder RC, Ray R, Blume S, Miller DM: Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters. Biochemistry. 1991, 30: 4290-4297. 10.1021/bi00231a027.View ArticleGoogle Scholar
- Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS, Kwon TK: Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther. 2006, 5: 2737-2746. 10.1158/1535-7163.MCT-06-0426.View ArticleGoogle Scholar
- Atossa S, Margot F, Yu M: Increasind expression of the pro-apoptotic Bcl2 family member PUMA is required for mitochondrial release of cytochrome C and the apoptosis associated with skeletal myoblast differentiation. Apoptosis. 2007, 12: 2143-2154. 10.1007/s10495-007-0135-z.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.